This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.

Later-Line Options for Patients With PSMA-Positive mCRPC

Expert Discusses When to Perform PSMA PET Imaging for Metastatic CRPC

August 24, 2022

Daniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.

Targeted Radioligand Therapy Shows Efficacy in PSMA-Positive mCRPC

July 25, 2022

Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.